GSK (GSK) said Monday that the European Medicines Agency has agreed to review its prefilled syringe version of Shingrix, a vaccine for the prevention of shingles.
The company said the prefilled syringes do away with the need to mix separate vials before jabs.
The regulatory review follows the Jan. 8 US Food and Drug Administration acceptance of the prefilled syringes, the company said.
GSK said it is also considering submitting the product for review in other markets.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。